-
EnteroBiotix announces positive Phase 2 TrIuMPH results supporting EBX-102-02 as a potential first-in-class, oral, full-spectrum microbiome therapy for irritable bowel syndrome
Clinically meaningful improvements in global IBS symptom severity observed as early as Week 1 and sustained through...
Join our audience of
healthcare industry professionals